Business Wire2 天
U.S. Food and Drug Administration Approves Bristol Myers Squibb’s COBENFY™ (xanomeline ...
U.S. FDA Approves Bristol Myers Squibb’s COBENFY, a First-In-Class Muscarinic Agonist for the Treatment of Schizophrenia in Adults ...
Bristol-Myers wins FDA nod for first-of-its-kind antipsychotic
Bristol-Myers Squibb (BMY) stock rises as FDA approves Cobenfy as a ovel treatment for adults with the psychiatric disorder ...
PureTech-Invented KarXT Receives U.S. Food and Drug Administration Approval for the ...
Invented KarXT Receives U.S. Food and Drug Administration Approval for the Treatment of Schizophrenia in Adults ...
FDA Approves Drug with New Mechanism of Action for Treatment of Schizophrenia
Today, the U.S. Food and Drug Administration approved Cobenfy (xanomeline and trospium chloride) capsules for oral use for the treatment of schizophrenia in adults. It is the first antipsychotic drug ...